MCMin Sung Chung

Min Sung Chung

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Min Sung Chung has a total of 146 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of the interruption of tamoxifen for pregnancy on the recurrence and survival outcomes among young women with breast cancer

    by Chihwan David Cha, Somin Jeon, Jihyun Keum, Shin Jeong Pak, Boyoung Park, Min Sung Chung

  • Open Access

    Prognostic difference between early breast cancer patients with HER2 low and HER2 zero status

    by Chihwan David Cha, Kyung Eun Kim, Jungbin Kim, Eunhae Um, Nayeon Choi, Jungsun Lee, Geumhee Gwak, Jae Il Kim, Min Sung Chung

    We aimed to investigate the differences in prognosis between patients with HER2-low and HER2-zero status. This retrospective cohort study conducted at multi-institution included 1627 patients diagnosed with HER2-low or HER2-zero breast cancer (stages I–III). Survival analysis after propensity score matching was used. In total, 445 patients with HER2-low and 707 patients with HER2-zero status were included. The median follow-up was 92.7 months. Locoregional and distant recurrence-free survival were comparable between patients with HER2-low and HER2-zero status (p = 0.872, p = 0.746, respectively). HER2-low status did not affect overall survival. However, in subgroups with lymph node metastases, patients with HER2-low status showed better recurrence-free survival compared with that of patients with HER2-zero status (p = 0.033). In conclusion, survival outcomes were comparable between patients with HER2-low and HER2-zero breast cancer. More studies are needed to validate our findings and examine the biological mechanism underlying these prognostic differences.


  • Open Access

    A Randomized Trial of Sentinel Node Biopsy Omission After Neoadjuvant Systemic Therapy in Clinically Node-Negative or Selected Node-Positive Breast Cancer

    by Ji-Jung Jung, Hee Jeong Kim, Byung Joo Chae, Eun-Kyu Kim, Jee Hyun Ahn, Joon Jeong, Seeyoun Lee, Seung Pil Jung, Joohyun Woo, Junwon Min, et al.

    Jung JJ, et al. J Breast Cancer. 2025 Nov;28:e42. https://doi.org/10.4048/jbc.2025.0157


  • Adverse effects of tamoxifen treatment on bone mineral density in premenopausal patients with breast cancer: a systematic review and meta-analysis

    by Soo Jin Lee, Chihwan David Cha, Hanpyo Hong, Yun Young Choi, Min Sung Chung

    Background It is well known that adjuvant tamoxifen treatment for breast cancer in postmenopausal women decreased bone loss. However, the effects of adjuvant tamoxifen therapy on bone mineral density (BMD) in premenopausal patients with breast cancer remains uncertain. Tamoxifen would have a potential impact of premenopausal BMD on health. The aim of this meta-analysis was to assess this in premenopausal women with primary breast cancer. Methods Through April 2020, studies reporting BMD changes of lumbar spine or hip in premenopausal women with primary breast cancer treated with adjuvant tamoxifen and tamoxifen plus chemotherapy or ovarian function suppression (OFS) were collected from EMBASE and PubMed. The meta-analysis was performed using random effects model of the standardized mean difference (SMD) of BMD in patients. Results A total of 1432 premenopausal patients were enrolled in eight studies, involving 198 patients treated with tamoxifen alone in three studies. After a 3-year median follow-up, adjuvant tamoxifen decreased the lumbar spinal and hip BMD by as much as an SMD of −1.17 [95% confidence interval (CI); −1.58 to −0.76)] and −0.66 (95% CI, −1.55 to 0.23), respectively. In subgroup analysis in patients treated adjuvant tamoxifen and tamoxifen plus chemotherapy or OFS according to follow-up duration, the bone change of < 3 years follow-up group was −0.03 SMD (95% CI, −0.47 to 0.41) and that of ≥ 3 years follow-up group was −1.06 SMD (95% CI, −1.48 to −0.64). Compared with patients who received tamoxifen alone, patients who received combination therapy with chemotherapy or OFS showed lesser bone loss at the lumbar spine. Conclusions Our meta-analysis demonstrated that adjuvant tamoxifen therapy in premenopausal patients caused bone loss after 3 years of follow-up, especially at the lumbar spines. For a definite evaluation of the adverse effects of tamoxifen on bone, it is necessary to accumulate more relevant studies.


  • Open Access

    ASAP1 Expression in Invasive Breast Cancer and Its Prognostic Role

    by Hosub Park, Hwangkyu Son, Hyebin Cha, Kihyuk Song, Seongsik Bang, Seungyun Jee, Hyunsung Kim, Jaekyung Myung, Su-Jin Shin, Chihwan Cha, et al.

    Breast cancer is a major global health burden with high morbidity and mortality rates. Previous studies have reported that increased expression of ASAP1 is associated with poor prognosis in various types of cancer. This study was conducted on 452 breast cancer patients who underwent surgery at Hanyang University Hospital, Seoul, South Korea. Data on clinicopathological characteristics including molecular pathologic markers were collected. Immunohistochemical staining of ASAP1 expression level were used to classify patients into high and low groups. In total, 452 cases low ASAP1 expression group was associated with significantly worse recurrence-free survival (p = 0.029). In ER-positive cases (n = 280), the low ASAP1 expression group was associated with significantly worse overall survival (p = 0.039) and recurrence-free survival (p = 0.029). In multivariate cox analysis, low ASAP1 expression was an independent significant predictor of poor recurrence-free survival in the overall patient group (hazard ratio = 2.566, p = 0.002) and ER-positive cases (hazard ratio = 4.046, p = 0.002). In the analysis of the TCGA dataset, the low-expression group of ASAP1 protein demonstrated a significantly poorer progression-free survival (p = 0.005). This study reports that low ASAP1 expression was associated with worse recurrence-free survival in invasive breast cancer.


  • Open Access

    Prognostic Implication of YY1 and CP2c Expression in Patients with Primary Breast Cancer

    by Chihwan David Cha, Seung Han Son, Chul Geun Kim, Hosub Park, Min Sung Chung

    Yin Yang 1 (YY1) is a transcription factor that regulates epigenetic pathways and protein modifications. CP2c is a transcription factor that functions as an oncogene to regulate cell proliferation. YY1 is known to interact with CP2c to suppress CP2c’s transcriptional activity. This study aimed to investigate YY1 and CP2c expression in breast cancer and prognostic implications. In this study, YY1 and CP2c expression was evaluated using immunohistochemical staining, Western blot and RT-PCR assays. Of 491 patients with primary breast cancer, 138 patients showed YY1 overexpression. Luminal subtype and early stage were associated with overexpression (p < 0.001). After a median follow-up of 68 months, YY1 overexpression was found to be associated with a better prognosis (disease-free survival rates of 92.0% vs. 79.2%, p = 0.014). In Cox proportional hazards model, YY1 overexpression functioned as an independent prognostic factor after adjustment of hormone receptor/HER2 status and tumor size (hazard ratio of 0.50, 95% CI 0.26–0.98, p = 0.042). Quantitative analysis of YY1 and CP2c protein expression in tumors revealed a negative correlation between them. In conclusion, YY1 overexpression is a favorable prognostic biomarker in patients with breast cancer, and it has a negative correlation with CP2c at the protein level.


  • Association of Fermented Products with Risk of Cancer Recurrence and Mortality among Breast Cancer Survivors: A Prospective Cohort Study

    by Jubin Yang, Min Sung Chung, Yong Soon Park

    We hypothesized that the intake of fermented soy and dairy products, but not fermented vegetable products, was associated with reduced cancer recurrence and mortality in breast cancer survivors. Women (n = 606) who underwent dietary survey using a 24-h recall within 3 years of breast cancer surgery were recruited, and were followed up for a mean of 89 mo,. Cox proportional hazards regression analysis showed that the risk of cancer recurrence was inversely associated with the intake of fermented soy products (Hazard ratios (HRs):0.976, 95% confidence intervals (CI):0.95–0.99) and fermented dairy products (HRs:0.992, 95% CI:0.98–0.99). Furthermore, the risk of cancer recurrence was inversely associated with the intake of fermented soy products in hormone receptor-positive (HRs:0.296, 95% CI:0.11–0.79), estrogen receptor-positive (HRs:0.971, 95% CI:0.94–0.99), and progesterone receptor-positive (HRs:0.972, 95% CI:0.94–0.99) patients. Mortality was inversely associated with the intake of fermented soy products (HRs:0.967, 95% CI:0.93–0.99). Disease-free survival (P = 0.001) and overall survival (P = 0.004) were positively associated with intake of fermented soy products. Intake of fermented vegetable products had no significant effect on cancer recurrence or mortality. This study suggests that the intake of fermented soy and dairy could be beneficial in preventing cancer recurrence.


  • Open Access

    Prognostic implication of YY1 and CP2c expression in patients with primary breast cancer

    by Min Sung Chung, Chihwan Cha, Seung Han Son, Chul Geun Kim, Hosub Park

    Background YY1 is transcription factor that regulates differential epigenetic pathways and protein modifications. CP2c is transcription factor that functions as oncogene to regulate cancer cell proliferation. YY1 is known to interact with CP2c to suppress CP2c’s transcriptional activity. However, it is unknown whether YY1 has prognostic significance in breast cancer. Thus, we aimed to investigate YY1 and CP2c expression in breast cancer and prognostic implications. Methods Clinical information and tissues were obtained from 491 patients with invasive breast cancer. YY1 expression was evaluated using immunohistochemical staining and patients were divided into two groups according to H-score. Western blot and RT-PCR assays were used for quantifications of YY1 and CP2c mRNA and protein expression. Results Of 491 patients with breast cancer, 138 patients showed YY1 overexpression. Luminal subtype, and early stage were associated with overexpression. After follow-up of 68 months, YY1 overexpression was found to be associated with better prognosis. In Cox proportional hazards model, YY1 overexpression functioned as independent prognostic factor after adjustment of ER/HER2 status and tumor size. Quantitative analysis of YY1 and CP2c protein expression in tumor revealed negative correlation between them. Conclusions YY1 overexpression is a favorable prognostic biomarker in patients with breast cancer, and it has negative correlation with CP2c.

  • Open Access

    Adverse Effects of Tamoxifen Treatment on Bone Mineral Density in Premenopausal Patients with Breast Cancer: A Systematic Review and Meta-Analysis

    by Soo Jin Lee, Chihwan Cha, Hanpyo Hong, Yun Young Choi, Min Sung Chung

    The effects of adjuvant tamoxifen therapy on bone mineral density (BMD) in premenopausal patients with breast cancer remains uncertain and, the aim of this meta-analysis was to assess this in premenopausal women with primary breast cancer. Through April 2020, studies reporting BMD changes of lumbar spine or hip in premenopausal women with primary breast cancer treated with adjuvant tamoxifen and tamoxifen plus chemotherapy or ovarian function suppression (OFS) were collected from EMBASE and PubMed. The pooled analysis was performed using random effects model of the standardized mean difference (SMD) of BMD in patients. A total of 1,432 premenopausal patients from eight studies were included. After a 3-year median follow-up, adjuvant tamoxifen decreased the lumbar spinal and hip BMD by as much as an SMD of -1.17 and − 0.66, respectively. Compared with patients who received tamoxifen alone, patients who received combination therapy with chemotherapy or OFS showed lower bone loss compared with tamoxifen alone at the lumbar spine. Our meta-analysis demonstrated that adjuvant tamoxifen therapy in premenopausal patients caused bone loss after 3 years of follow-up, especially at the lumbar spines. For a definite evaluation of the adverse effects of tamoxifen on bone, it is necessary to accumulate more relevant studies.